UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair

Clinical cancer research, 2017-07, Vol.23 (13), p.3232-3240

2017

Volltextzugriff (PDF)

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms

Molecular cancer therapeutics, 2015-09, Vol.14 (9), p.2004-2013

2015

Volltextzugriff (PDF)

A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors

The oncologist (Dayton, Ohio), 2024-01, Vol.29 (1), p.e131-e140

2024

Volltextzugriff (PDF)

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Blood, 2024-09, Vol.144 (13), p.1374-1386

2024

Volltextzugriff (PDF)

The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells

Molecular cancer therapeutics, 2012-08, Vol.11 (8), p.1781-1788

2012

Volltextzugriff (PDF)

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib

Oncotarget, 2020-01, Vol.11 (3), p.216-236

2020

Volltextzugriff (PDF)

Suppression of p53 and p21CIP1/WAF1 Reduces Arsenite-Induced Aneuploidy

Chemical research in toxicology, 2010-02, Vol.23 (2), p.357-364

2010

Volltextzugriff (PDF)

Exit from Arsenite-Induced Mitotic Arrest Is p53 Dependent

Environmental health perspectives, 2006-09, Vol.114 (9), p.1401-1406

2006

Volltextzugriff (PDF)

Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study

Blood, 2023-11, Vol.142 (Supplement 1), p.3269-3269

2023

Volltextzugriff (PDF)

Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3089-3089

2020

Volltextzugriff (PDF)

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

Clinical lung cancer, 2021-11, Vol.22 (6), p.531-540

2021

Volltextzugriff (PDF)

Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings

The oncologist (Dayton, Ohio), 2020-11, Vol.25 (11), p.e1628-e1639

2020

Volltextzugriff (PDF)

Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real-world data

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1042-1042

2019

Volltextzugriff (PDF)

Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D)

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.92-92

2018

Volltextzugriff (PDF)

p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1

The Journal of pharmacology and experimental therapeutics, 2006-07, Vol.318 (1), p.142

2006

Volltextzugriff (PDF)

Sodium arsenite alters cell cycle progression and induces apoptosis in melanoma cell lines

The FASEB journal, 2007, Vol.21 (6), p.A806-A806

2007

Volltextzugriff (PDF)

Abstract A108: LY2606368, a second generation Chk1 inhibitor, inhibits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A108-A108

2011

Volltextzugriff (PDF)

Suppression of p53 and p21 CIP1/WAF1 Reduces Arsenite-Induced Aneuploidy

Chemical research in toxicology, 2010-02, Vol.23 (2), p.357-364

2010

Volltextzugriff (PDF)

p53 Suppression of Arsenite-Induced Mitotic Catastrophe Is Mediated by p21 CIP1/WAF1

The Journal of pharmacology and experimental therapeutics, 2006-07, Vol.318 (1), p.142-151

2006

Volltextzugriff (PDF)

Sensitivity to sodium arsenite depends upon susceptibility to mitotic arrest-associated apoptosis

McNeely, Samuel C

2007

Volltextzugriff (PDF)

Sensitivity to sodium arsenite depends upon susceptibility to mitotic arrest-associated apoptosis

McNeely, Samuel C

2007

Volltextzugriff (PDF)

Arsenic: A potential chemotherapeutic for melanoma

McNeely, Samuel C

2005

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(35)

Publikationsform

Sprache

Englisch
(57)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Humans
(14)
Life Sciences & Biomedicine
(12)
Oncology
(8)
Physical Sciences
(7)
Female
(6)
Physics
(6)
Physics, Fluids & Plasmas
(6)
Adult
(4)
Male
(4)
Middle Aged
(4)
Toxicology
(4)
Aged
(3)
Cell Cycle - Drug Effects
(3)
Fast Ions
(3)
Simulation
(3)
Stellarator
(3)
Abdomen
(2)
Aged, 80 And Over
(2)
Antineoplastic Agents - Pharmacology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms

A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR (CBTKI) PRE‐TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY

Suppression of p53 and p21CIP1/WAF1 Reduces Arsenite-Induced Aneuploidy

Exit from Arsenite-Induced Mitotic Arrest Is p53 Dependent

Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study

Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study

Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings

Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real-world data

Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D)

p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1

Sodium arsenite alters cell cycle progression and induces apoptosis in melanoma cell lines

Abstract A108: LY2606368, a second generation Chk1 inhibitor, inhibits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents

Suppression of p53 and p21 CIP1/WAF1 Reduces Arsenite-Induced Aneuploidy

p53 Suppression of Arsenite-Induced Mitotic Catastrophe Is Mediated by p21 CIP1/WAF1

Sensitivity to sodium arsenite depends upon susceptibility to mitotic arrest-associated apoptosis

Sensitivity to sodium arsenite depends upon susceptibility to mitotic arrest-associated apoptosis

Arsenic: A potential chemotherapeutic for melanoma

Aktive Filter

Suchergebnisse filtern